Cargando…

Imprinting of Mesenchymal Stromal Cell Transcriptome Persists even after Treatment in Patients with Multiple Myeloma

Introduction. Multiple myeloma (MM) is a B-cell neoplasm characterized by clonal expansion of malignant plasma cells (MM cells) in the bone-marrow (BM) compartment. BM mesenchymal stromal cells (MSC) from newly diagnosed MM patients were shown to be involved in MM pathogenesis and chemoresistance. T...

Descripción completa

Detalles Bibliográficos
Autores principales:	Lemaitre, Léa, Do Souto Ferreira, Laura, Joubert, Marie-Véronique, Avet-Loiseau, Hervé, Martinet, Ludovic, Corre, Jill, Couderc, Bettina
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2020
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7312921/ https://www.ncbi.nlm.nih.gov/pubmed/32481768 http://dx.doi.org/10.3390/ijms21113854

Ejemplares similares

Toll-like receptor 4 selective inhibition in medullar microenvironment alters multiple myeloma cell growth
por: Lemaitre, Léa, et al.
Publicado: (2022)

Functional Comparison between Healthy and Multiple Myeloma Adipose Stromal Cells
por: Espagnolle, Nicolas, et al.
Publicado: (2020)

Multiple Myeloma: Heterogeneous in Every Way
por: Schavgoulidze, Anaïs, et al.
Publicado: (2021)

Risk and Response-Adapted Treatment in Multiple Myeloma
por: Cazaubiel, Titouan, et al.
Publicado: (2020)

Responses in multiple myeloma should be assigned according to serum, not urine, free light chain measurements
por: Dejoie, Thomas, et al.
Publicado: (2018)

Monoallelic deletion of BCMA is a frequent feature in multiple myeloma
por: Samur, Mehmet Kemal, et al.
Publicado: (2023)

Front-line therapies for elderly patients with transplant-ineligible multiple myeloma and high-risk cytogenetics in the era of novel agents
por: Avet-Loiseau, Herve, et al.
Publicado: (2018)

Optimizing therapy for del(17p) multiple myeloma
por: Avet-Loiseau, Hervé, et al.
Publicado: (2017)

Prognostic impact of translocation t(14;16) in multiple myeloma according to the presence of additional genetic lesions
por: Schavgoulidze, Anaïs, et al.
Publicado: (2023)

DNA hydroxymethylation is associated with disease severity and persists at enhancers of oncogenic regions in multiple myeloma
por: Alberge, Jean-Baptiste, et al.
Publicado: (2020)

In-depth analysis of alternative splicing landscape in multiple myeloma and potential role of dysregulated splicing factors
por: Aktas Samur, Anil, et al.
Publicado: (2022)

Frequent Engagement of RelB Activation Is Critical for Cell Survival in Multiple Myeloma
por: Cormier, Françoise, et al.
Publicado: (2013)

Genome-Wide Somatic Alterations in Multiple Myeloma Reveal a Superior Outcome Group
por: Samur, Mehmet Kemal, et al.
Publicado: (2020)

The shaping and functional consequences of the dosage effect landscape in multiple myeloma
por: Samur, Mehmet K, et al.
Publicado: (2013)

TCR-independent CD137 (4–1BB) signaling promotes CD8(+)-exhausted T cell proliferation and terminal differentiation
por: Pichler, Andrea C., et al.
Publicado: (2023)

Tumor cells educate mesenchymal stromal cells to release chemoprotective and immunomodulatory factors
por: Le Naour, Augustin, et al.
Publicado: (2019)

The location of the t(4;14) translocation breakpoint within the NSD2 gene identifies a subset of patients with high-risk NDMM
por: Stong, Nicholas, et al.
Publicado: (2023)

Expressed fusion gene landscape and its impact in multiple myeloma
por: Cleynen, A., et al.
Publicado: (2017)

Classify Hyperdiploidy Status of Multiple Myeloma Patients Using Gene Expression Profiles
por: Li, Yingxiang, et al.
Publicado: (2013)

Senescence-Driven Inflammatory and Trophic Microenvironment Imprints Mesenchymal Stromal/Stem Cells in Osteoarthritic Patients
por: Fusi, Giuseppe, et al.
Publicado: (2023)

Deciphering the chronology of copy number alterations in Multiple Myeloma
por: Aktas Samur, Anil, et al.
Publicado: (2019)

Prognostic utility of intact immunoglobulin Ig′κ/Ig′λ ratios in multiple myeloma patients
por: Bradwell, A, et al.
Publicado: (2013)

Heavy+light chain monitoring correlates with clinical outcome in multiple myeloma patients
por: Michallet, M, et al.
Publicado: (2018)

Logic programming reveals alteration of key transcription factors in multiple myeloma
por: Miannay, Bertrand, et al.
Publicado: (2017)

Cerebrospinal Fluid Penetrance of Daratumumab in Leptomeningeal Multiple Myeloma
por: Zajec, Marina, et al.
Publicado: (2020)

Clinical benefit of ixazomib plus lenalidomide‐dexamethasone in myeloma patients with non‐canonical NF‐κB pathway activation
por: Dash, Ajeeta B., et al.
Publicado: (2020)

Early relapse after autologous transplant for myeloma is associated with poor survival regardless of cytogenetic risk
por: Corre, Jill, et al.
Publicado: (2020)

Whole-genome analysis identifies novel drivers and high-risk double-hit events in relapsed/refractory myeloma
por: Ansari-Pour, Naser, et al.
Publicado: (2023)

Measurable Residual Disease Testing in Multiple Myeloma Routine Clinical Practice: A Modified Delphi Study
por: Ramasamy, Karthik, et al.
Publicado: (2023)

Management of patients with multiple myeloma in the era of COVID-19 pandemic: a consensus paper from the European Myeloma Network (EMN)
por: Terpos, Evangelos, et al.
Publicado: (2020)

The H19 locus: regulatory function of an imprinted non coding RNA in embryonic development
por: Monnier, Paul, et al.
Publicado: (2013)

Non-overlapping Control of Transcriptome by Promoter- and Super-Enhancer-Associated Dependencies in Multiple Myeloma
por: Fulciniti, Mariateresa, et al.
Publicado: (2018)

Astronomy for all: a reality even for people with disabilities
por: Petitdemange, Ludovic
Publicado: (2021)

Analysis of a Compartmental Model of Endogenous Immunoglobulin G Metabolism with Application to Multiple Myeloma
por: Kendrick, Felicity, et al.
Publicado: (2017)

Long-term TE persistence even without beneficial insertion
por: Kremer, Stefan C., et al.
Publicado: (2021)

Persistent service even in disruptive times: an introduction to resilience engineering
por: Capdarest-Arest, Nicole, et al.
Publicado: (2022)

Biallelic loss of BCMA as a resistance mechanism to CAR T cell therapy in a patient with multiple myeloma
por: Samur, Mehmet Kemal, et al.
Publicado: (2021)

Chimeric antigen receptors containing the OX40 signalling domain enhance the persistence of T cells even under repeated stimulation with multiple myeloma target cells
por: Tan, Jingwen, et al.
Publicado: (2022)

The DNA methylation landscape of multiple myeloma shows extensive inter- and intrapatient heterogeneity that fuels transcriptomic variability
por: Derrien, Jennifer, et al.
Publicado: (2021)

Timing the initiation of multiple myeloma
por: Rustad, Even H., et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_pcf8lm5tclnur17l817kttdl3u